MAP2K7 and lung carcinoma: To determine whether RPS5 is involved in sensitivity to MEK inhibition, we knocked down RPS5 using siRNA in HCT116 cells and A549 human lung cancer cells harboring RAS mutation (Fig. 3A and B).